Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 14/20 | 0.50 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700510 | 0.78 | PTPN11 (0.57) | PTPN11HTR1ADRD4HTR2ASLC6A4 | |
| SCHEMBL5239673 | 0.78 | CNR2 (0.58) | HTR1ADRD4HTR2ASLC6A4DRD3 | |
| SCHEMBL645763 | 0.77 | PTPN11 (0.54) | PTPN11KCNH2CNR2 | |
| SCHEMBL647719 | 0.76 | HSD17B10 (0.58) | PTPN11 | |
| SCHEMBL3442195 | 0.75 | GPR119 (0.59) | HTR1ADRD4HTR2ASLC6A4DRD3 | |
| SCHEMBL16773016 | 0.75 | CNR2 (0.69) | KCNH2CNR2 | |
| SCHEMBL647552 | 0.73 | PTPN11 (0.60) | PTPN11RET | |
| SCHEMBL649950 | 0.73 | OGA (0.48) | PTPN11 | |
| SCHEMBL648751 | 0.73 | KDM4E (0.54) | PTPN11 | |
| SCHEMBL6703611 | 0.72 | RET (0.56) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | PTPN11 1064/4885RET 3084/4885HTR1A 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.